Molecular targets for cancer chemoprevention

Nature Reviews Drug Discovery

Volumn 8, Issue 3, 2009, Pages 213-225

  William Jr , William N ^a   Heymach, John V ^a   Kim, Edward S ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; AZACITIDINE; BEVACIZUMAB; CELECOXIB; CETUXIMAB; EFLORNITHINE; ERLOTINIB; FINASTERIDE; GEFITINIB; HEPATITIS B VACCINE; LAPATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; PANITUMUMAB; PLACEBO; RALOXIFENE; RETINOID; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SORAFENIB; SULINDAC; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRACEVA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; WART VIRUS VACCINE;

ADENOMATOUS POLYP; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CATARACT; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLORECTAL ADENOMA; DRUG TARGETING; ENDOMETRIUM CANCER; FAMILIAL COLON POLYPOSIS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEAD AND NECK CANCER; HEPATITIS B; HETEROZYGOSITY LOSS; HUMAN; HYPERPLASIA; INTRADUCTAL CARCINOMA; KIDNEY CANCER; LEUKOPLAKIA; LIVER CELL CARCINOMA; LUNG CANCER; META ANALYSIS; MYELODYSPLASTIC SYNDROME; POSTMENOPAUSE; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; UTERINE CERVIX CANCER; VON HIPPEL LINDAU DISEASE;

ANIMALS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; RISK FACTORS; VACCINES;

EID: 61649113744     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2663     Document Type: Review

References (129)

1. Sporn, M. B., Dunlop, N. M., Newton, D. L. & Smith, J. M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35, 1332-1338 (1976).
2. O'Shaughnessy, J. A. et al. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin. Cancer Res. 8, 314-346 (2002).
3. Kelloff, G. J. et al. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin. Cancer Res. 12, 3661-3697 (2006).
4. Lippman, S. M. & Hong, W. K. Cancer prevention science and practice. Cancer Res. 62, 5119-5125 (2002).
5. Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885-895 (2006).
6. Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873-884 (2006).
7. Baron, J. A. et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 1674-1682 (2006).
8. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998).
9. Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295, 2727-2741 (2006).
10. Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
11. Amos, C. I. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genet. 40, 616-622 (2008).
12. Hung, R. J. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
13. Thorgeirsson, T. E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
14. Mao, L. et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J. Natl Cancer Inst. 90, 1545-1551 (1998).
15. Spira, A. et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl Acad. Sci. USA 101 10143-10148 (2004).
16. Park, I. W. et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J. Natl Cancer Inst. 91, 1863-1868 (1999).
17. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genet. 38, 468-473 (2006).
18. Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
19. Spitz, M. R. et al. An expanded risk prediction model of lung cancer. Cancer Prev. Res. 1, 250-254 (2008).
20. Spitz, M. R. et al. A risk model for prediction of lung cancer. J. Natl Cancer Inst. 99, 715-726 (2007).
21. Fisher, B. et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353, 1993-2000 (1999).
22. Rockhill, B., Spiegelman, D., Byrne, C., Hunter, D. J. & Colditz, G. A. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J. Natl Cancer Inst. 93, 358-366 (2001).
23. Degnim, A. C. et al. Stratification of breast cancer risk in women with atypia: A Mayo cohort study. J. Clin. Oncol. 25, 2671-2677 (2007).
24. Freedman, A. N. et al. Cancer risk prediction models: A workshop on development, evaluation, and application. J. Natl Cancer Inst. 97, 715-723 (2005).
25. Gauthier, M. L. et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 12, 479-491 (2007).
26. Belinsky, S. A. et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66, 3338-3344 (2006).
27. Beane, J. et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev. Res. 1 56-64 (2008).
28. Galipeau, P. C. et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 4, e67 (2007).
29. Lee, J. J. et al. Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin. Cancer Res. 6, 1702-1710 (2000).
30. Rosin, M. P. et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 6 357-362 (2000).
31. Rosin, M. P. et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 62, 6447-6450 (2002).
32. Izzo, J. G. et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J. Natl Cancer Inst. 95, 198-205 (2003).
33. Chang, M. H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336, 1855-1859 (1997).
34. Garland, S. M. et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356, 1928-1943 (2007).
35. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
36. Paavonen, J. et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 2161-2170 (2007).
37. Hildesheim, A. et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298, 743-753 (2007).
38. Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096-1100 (2008).
39. Blaser, M. J. Understanding microbe-induced cancers. Cancer Prev. Res. 1, 15-20 (2008).
40. Correa, P. et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J. Natl Cancer Inst. 92, 1881-1888 (2000).
41. You, W. C. et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Natl Cancer Inst. 98, 974-983 (2006).
42. Finn, O. J. Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
43. Garcia-Hernandez Mde, L., Gray, A., Hubby, B., Klinger, O. J. & Kast, W. M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 68, 861-869 (2008).
44. Dhodapkar, M. V., Krasovsky, J., Osman, K. & Geller, M. D. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med. 198, 1753-1757 (2003).
45. Spisek, R. & Dhodapkar, M. V. Immunoprevention of cancer. Hematol. Oncol. Clin. North Am. 20, 735-750 (2006).
46. Hong, W. K. et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315, 1501-1505 (1986).
47. Hong, W. K. et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323, 795-801 (1990).
48. Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C. & Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up. J. Natl Cancer Inst. 86, 140-141 (1994).
49. Lippman, S. M. et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N. Engl. J. Med. 328, 15-20 (1993).
50. Papadimitrakopoulou, V. A. et al. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: Long-term follow-up. J. Natl Cancer Inst. 89, 257-258 (1997).
51. Xu, X. C. et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 54, 3580-3587 (1994).
52. Lotan, R. et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med. 332, 1405-1410 (1995).
53. Xu, X. C. et al. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res. 55 5507-5511 (1995).
54. Mao, L. et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med. 2, 682-685 (1996).
55. Hong, W. K., Spitz, M. R. & Lippman, S. M. Cancer chemoprevention in the 21st century: Genetics, risk modeling, and molecular targets. J. Clin. Oncol. 18, 9S-18S (2000).
56. Cuzick, J. et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360, 817-824 (2002).
57. Powles, T. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101 (1998).
58. Powles, T. J., Ashley, S., Tidy, A., Smith, I. E. & Dowsett, M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl Cancer Inst. 99, 283-290 (2007).
59. Veronesi, U. et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352, 93-97 (1998).
60. Cuzick, J. et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300 (2003).
61. Cuzick, J. et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst. 99, 272-282 (2007).
62. Port, E. R., Montgomery, L. L., Heerdt, A. S. & Borgen, P. I. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann. Surg. Oncol. 8, 580-585 (2001).
63. Fabian, C. J. & Kimler, B. F. Selective estrogen-receptor modulators for primary prevention of breast cancer. J. Clin. Oncol. 23, 1644-1655 (2005).
64. Scardino, P. T. The prevention of prostate cancer - the dilemma continues. N. Engl. J. Med. 349, 297-299 (2003).
65. Thompson, I. M. et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J. Urol. 178, 107-109; discussion 110 (2007).
66. Lucia, M. S. et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemo-prevention. Cancer Prev. Res. 1, 167-173 (2008).
67. Lucia, M. S. et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 99 1375-1383 (2007).
68. Redman, M. W. et al. Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer Prev. Res. 1, 174-181 (2008).
69. Pinsky, P., Parnes, H. & Ford, L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev. Res. 1, 182-186 (2008).
70. Logothetis, C. J. & Schellhammer, P. F. High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev. Res. 1, 151-152 (2008).
71. Lotan, Y., Cadeddu, J. A., Lee, J. J., Roehrborn, C. G. & Lippman, S. M. Implications of the prostate cancer prevention trial: A decision analysis model of survival outcomes. J. Clin. Oncol. 23, 1911-1920 (2005).
72. Lippman, S. M. & Lee, J. J. Reducing the "risk" of chemoprevention: defining and targeting high risk - 2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res. 66, 2893-2903 (2006).
73. Giardiello, F. M. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313-1316 (1993).
74. Benamouzig, R. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 125, 328-336 (2003).
75. Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003).
76. Logan, R. F., Grainge, M. J., Shepherd, V. C., Armitage, N. C. & Muir, K. R. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134, 29-38 (2008).
77. Sandler, R. S. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890 (2003).
78. Flossmann, E. & Rothwell, P. M. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369, 1603-1613 (2007).
79. Steinbach, G. et al. The effect of celecoxib, a cyclo-oxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
80. Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
81. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
82. Bertagnolli, M. M., Zauber, A. G. & Hawk, E. T. The Adenoma Prevention with Celecoxib (APC) trial: Five-year efficacy and safety results [abstract]. Proc. 99th Annu. Meet. Am. Assoc. Cancer Res. Abstr. LB-141 (San Diego, California, 2008).
83. Psaty, B. M. & Potter, J. D. Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med. 355, 950-952 (2006).
84. Martino, S. et al. The role of selective estrogen receptor modulators in the prevention of breast cancer: Comparison of the clinical trials. Oncologist 9, 116-125 (2004).
85. Solomon, S. D. et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation 117, 2104-2113 (2008).
86. Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131-2142 (2007).
87. Markowitz, S. D. Aspirin and colon cancer - targeting prevention? N. Engl. J. Med. 356, 2195-2198 (2007).
88. Abbruzzese, J. L. & Lippman, S. M. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6, 321-326 (2004).
89. Lippman, S. M. & Heymach, J. V. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin. Cancer Res. 13, 4035-4041 (2007).
90. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
91. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812 (1999).
92. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
93. Pore, N. et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 66, 3197-3204 (2006).
94. Bratslavsky, G., Sudarshan, S., Neckers, L. & Linehan, W. M. Pseudohypoxic pathways in renal cell carcinoma. Clin. Cancer Res. 13, 4667-4671 (2007).
95. Iliopoulos, O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J. Clin. Oncol. 24, 5593-5600 (2006).
96. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genet. 30, 406-410 (2002).
97. Brugarolas, J. & Kaelin, W. G. Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6, 7-10 (2004).
98. Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R. & Kaelin, W. G. Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158 (2003).
99. Bach, P. B. et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst. 95, 470-478 (2003).
100. Cho, N. L. et al. Aberrant crypt foci in the Adenoma Prevention with Celecoxib trial. Cancer Prev. Res. 1, 21-31 (2008).
101. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
102. Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2 e313 (2005).
103. Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485-495 (2006).
104. Tang, X. et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 65, 7568-7572 (2005).
105. Ji, H. et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl Acad. Sci. USA 103, 7817-7822 (2006).
106. Bell, D. W. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genet. 37, 1315-1316 (2005).
107. Lee, H. Y. et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J. Natl Cancer Inst. 96, 1536-1548 (2004).
108. 473) expression in bronchial dysplasia: Implications for lung cancer prevention studies. Cancer Epidemiol. Biomarkers Prev. 12, 660-664 (2003).
109. Jin, Q. et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res. 67, 11630-11639 (2007).
110. Jyonouchi, H., Sun, S., Iijima, K., Wang, M. & Hecht, S. S. Effects of anti-7,8-dihydroxy-9, 10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Carcinogenesis 20, 139-145 (1999).
111. Wislez, M. et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 65, 3226-3235 (2005).
112. Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Med. 10, 594-601 (2004).
113. Strecker, T. et al. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J. Natl Cancer Inst. 101, 107-113 (2009).
114. Herbst, R. S. et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 25, 4743-4750 (2007).
115. + metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. 26 (suppl.), Abstr. 1015 (2008).
116. Torrance, C. J. et al. Combinatorial chemoprevention of intestinal neoplasia. Nature Med. 6, 1024-1028 (2000).
117. Sporn, M. B. Combination chemoprevention of cancer. Nature 287 107-108 (1980).
118. Gupta, R. A. & DuBois, R. N. Combinations for cancer prevention. Nature Med. 6, 974-975 (2000).
119. Meyskens, F. L. Jr. et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, doubleblind trial. Cancer Prev. Res. 1, 32-38 (2008).
120. Nigro, N. D., Bull., A. W. & Boyd, M. E. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil. J. Natl Cancer Inst. 77, 1309-1313 (1986).
121. Rao, C. V. et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51, 4528-4534 (1991).
122. Piazza, G. A. et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57, 2909-2915 (1997).
123. Meyskens, F. L. Jr. et al. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J. Natl Cancer Inst. 86, 1122-1130 (1994).
124. Meyskens, F. L. Jr. et al. Effect of alphadifluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J. Natl Cancer Inst. 90, 1212-1218 (1998).
125. Lippman, S. M. et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J. Natl Cancer Inst. 97, 94-102 (2005).
126. Hubner, R. A. et al. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin. Cancer Res. 14, 2303-2309 (2008).
127. Martinez, M. E. et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl Acad. Sci. USA 100, 7859-7864 (2003).
128. Papadimitrakopoulou, V. et al. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev. Res. 2, 14-21 (2009).
129. Papadimitrakopoulou, V. et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J. Clin. Oncol. 27, 599-604 (2009).